## **CLAIMS**

1. A compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof:

wherein

X and Z each represent CH or N;

 $R^1$ ,  $R^2$ , and  $R^3$ , which may be the same or different, represent a hydrogen atom,  $c_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{2-6}$ alkenyl,  $C_{2-6}$  alkynyl, nitro, or amino, which  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{2-6}$  alkenyl, and  $C_{2-6}$  alkynyl are optionally substituted by a halogen atom; hydroxyl; C1-4 alkoxy; C1-4 alkoxycarbonyl; amino on which one or two hydrogen atoms are optionally substituted by  $C_1$ alkyl optionally substituted by hydroxyl or  $C_{1-4}$  alkoxy; group  $R^{12}R^{13}N$ -C(=0)-0- wherein  $R^{12}$  and  $R^{13}$ , which may be the same or different, represent a hydrogen atom or  $C_{1-4}$  alkyl which alkyl is optionally substituted by hydroxyl or C1-4 alkoxy; or group  $R^{14}$ -(S)m- wherein  $R^{14}$  represents a unsaturated seten-membered threesaturated or to carbocyclic or heterocyclic group optionally substituted by  $C_{1-4}$  alkyl and m is 0 or 1;

R4 represents a hydrogen atom;

 $R^5$ ,  $R^6$ ,  $R^7$ , and  $R^8$ , which may be the same or different, represent a hydrogen atom, a halogen atom,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkylthio, nitro, or amino, provided that  $R^5$ ,  $R^6$ ,  $R^7$ , and  $R^8$  do not simultaneously represent a hydrogen atom;

PB'

 $R^9$  and  $R^{10}$ , which may be the same or different, represent a hydrogen atom,  $C_{1-6}$  alkyl, or  $C_{1-4}$  alkylcarbonyl, the alkyl portion of which  $C_{1-6}$  alkyl or  $C_{1-4}$  alkylcarbonyl is optionally substituted by a halogen atom;  $C_{1-4}$  alkoxy; amino which is optionally substituted by  $C_{1-4}$  alkyl optionally substituted by  $C_{1-4}$  alkoxy; or a saturated or unsaturated three— to seven-membered carbocyclic or heterocyclic group; and

 $R^{11}$  represents  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or  $C_{2-6}$  alkynyl (which  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, and  $C_{2-6}$  alkynyl each are optionally substituted by a halogen atom or  $C_{1-6}$  alkoxy), or  $R^{15}$ -( $CH_2$ )n- wherein n is an integer of 0 to 4 and  $R^{15}$  represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group which is optionally substituted by a halogen atom,  $C_{1-6}$  alkyl, or  $C_{1-6}$  alkoxy and is optionally condensed with other saturated or unsaturated three- to seven-membered carbocyclic ring or heterocyclic ring to form a bicyclic ring.

- 2. The compound according to claim 1, wherein  $R^1$ ,  $R^9$ , and  $R^{10}$  represent a hydrogen atom.
- 3. The compound according to claim 1, wherein  $R^1$  represents a hydrogen atom and one of or both  $R^9$  and  $R^{10}$  represent a group other than a hydrogen atom.
- 4. The compound according to claim 1, wherein X represents N or CH and Z represents CH.
- 5. A compound represented by formula (Ia) or a pharmaceutically acceptable salt or solvate thereof:

pulso

R23 R27 R28 R29 R26 R25 R25 (la)

wherein

X represents CH or N;

R21 and R22, which may be the same or different, represent unsubstituted C<sub>1-6</sub> alkoxy or group R<sup>31</sup>-(CH<sub>2</sub>)p-0wherein  $R^{31}$  represents a halogen atom, hydroxyl,  $C_{1-4}$ alkoxy, C1-4 alkoxycarbonyl, amino on which one or two hydrogen atoms are optionally substituted by  $C_{1-4}$  alkyl optionally substituted by hydroxyl or C1-4 alkoxy, group  $R^{12}R^{13}N-C(=0)-O-$  wherein  $R^{12}$  and  $R^{13}$ , which may be the same or different, represent a  $h\chi$ drogen atom or  $C_{1-4}$  alkyl which alkyl is optionally substituted by hydroxyl or C1-4 or group R14-(S)m- wherein R14 represents a unsaturated three to seven-membered saturated or carbocyclic or heterocyclic group optionally substituted by  $C_{1-4}$  alkyl and m is 0 or 1; and p is an integer of 1 to 6;

 $R^{23}$ ,  $R^{24}$ ,  $R^{25}$ , and  $R^{26}$ , which may be the same or different, represent a hydrogen atom, a halogen atom,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkylthio, nitro or amino, provided that  $R^{23}$ ,  $R^{24}$ ,  $R^{25}$ , and  $R^{26}$  do not simultaneously represent a hydrogen atom;

 $R^{27}$  and  $R^{28}$ , which may be the same or different, represent a hydrogen atom,  $C_{1-6}$  alkyl, or  $C_{1-4}$  alkylcarbonyl, the alkyl portion of which  $C_{1-6}$  alkyl or  $C_{1-4}$  alkylcarbonyl is optionally substituted by a halogen atom;  $C_{1-4}$  alkoxy; amino which is optionally substituted by  $C_{1-4}$  alkyl optionally substituted by  $C_{1-4}$  alkoxy; or a saturated or unsaturated three— to seven-membered

carbocyclic or heterocyclic group; and

 $R^{30}$  represents  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or  $C_{2-6}$ alkynyl (which  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, and  $C_{2-6}$  alkynyl each are optionally substituted by a halogen atom or C1-4 alkoxy), or  $R^{32}$ -(CH<sub>2</sub>)q- wherein q is an integer of 0 to 4 R32 represents a saturated or unsaturated sixmembered carbocyclic or keterocyclic group which is optionally substituted by a halogen atom, C1-4 alkyl, or condensed with other  $C_{1-4}$  alkoxy and is optionally unsaturated five- or six-membered saturated orcarbocyclic ring or heterocyclic ring to form a bicyclic ring.

6. The compound according to claim 5, wherein  $R^{21}$ and R22 represent unsubstituted C1-4 alkoxy.

 $\uparrow$ . The compound according to claim 5, wherein any one of  $R^{21}$  and  $R^{22}$  represents unsubstituted  $C_{1-4}$  alkoxy and the other represents group R31-(CH2)p-O-.

- 8. The compound according to claim 5, wherein at least one of  $R^{23}$ ,  $R^{24}$ ,  $R^{25}$ , and  $R^{26}$  represents a halogen atom.
- 9. The compound according to claim 5, wherein at least one of  $R^{23}$ ,  $R^{24}$ ,  $R^{25}$ , and  $R^{26}$  represents a chlorine atom or a fluorine atom.
- 10. The compound\according to claim 5, wherein at least one of  $R^{23}$ ,  $R^{24}$ ,  $R^{25}$ , and  $R^{26}$  represents  $C_{1-4}$  alkyl.
- 11. The compound according to claim 5, wherein two of R23, R24, R25, and R26 represent methyl and the remaining two represent a hydrogen atom.
- 12. The compound according to claim 5, wherein at least one of R23, R24, R25, and R26 represents nitro, amino,

 $C_{1-4}$  alkoxy, or  $C_{1-4}$  alkylthio.

- 13. The compound according to claim 5, wherein  $R^{23}$ ,  $R^{25}$ , and  $R^{26}$  represent a hydrogen atom and  $R^{24}$  represents a halogen atom,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, nitro, or amino.
- 14. The compound according to claim 5, wherein both  $R^{27}$  and  $R^{28}$  represent a hydrogen atom.
  - 15. The compound according to claim 5, wherein any one of or both  $R^{27}$  and  $R^{28}$  represent a group other than a hydrogen atom.
    - 16. The compound according to claim 5, wherein X represents CH or N;

R<sup>21</sup> and R<sup>22</sup> represent unsubstituted C<sub>1-4</sub> alkoxy;

 $R^{23}$ ,  $R^{25}$ , and  $R^{26}$  represent a hydrogen atom;

 $R^{24}$  represents a halogen atom,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, or nitro;

R<sup>27</sup> and R<sup>28</sup> represent a hydrogen atom; and

 $R^{29}$  represents  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or  $C_{2-6}$  alkynyl (which  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, and  $C_{2-6}$  alkynyl each are optionally substituted by a halogen atom or  $C_{1-4}$  alkoxy), or  $-(CH_2)q-R^{32}$  wherein q is an integer of 0 or 1 and  $R^{32}$  represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom,  $C_{1-4}$  alkyl, or  $C_{1-4}$  alkoxy.

17. The compound according to claim 5, wherein X represents CH or N;

 $R^{21}$  and  $R^{22}$  represent unsubstituted  $C_{1-4}$  alkoxy;

 $R^{23}$ ,  $R^{25}$ , and  $R^{26}$  represent a hydrogen atom;

 $R^{24}$  represents a halogen atom,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, or nitro;

any one of or both  $R^{27}$  and  $R^{28}$  represent a group other than a hydrogen atom; and

 $R^{29}$  represents  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or  $C_{2}$ .

alkynyl (which  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, and  $C_{2-6}$  alkynyl each are optionally substituted by a halogen atom or  $C_{1-4}$  alkoxy), or  $-(CH_2)q-R^{32}$  wherein q is an integer of 0 or 1 and  $R^{32}$  represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom,  $C_{1-4}$  alkyl, or  $C_{1-4}$  alkoxy.

18. The compound according to claim 5, wherein X represents CH or N;

 $R^{21}$  and  $R^{22}$  represent unsubstituted  $C_{1-4}$  alkoxy;

 $R^{23}$ ,  $R^{25}$ , and  $R^{26}$  represent a hydrogen atom;

 $R^{24}$  represents a halogen atom,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, or nitro;

R<sup>27</sup> represents a hydrogen atom;

R<sup>28</sup> represents a group other than a hydrogen atom; and

 $R^{29}$  represents  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or  $C_{2-6}$  alkynyl (which  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, and  $C_{2-6}$  alkynyl each are optionally substituted by a halogen atom or  $C_{1-4}$  alkoxy), or  $-(CH_2)q-R^{32}$  wherein q is an integer of 0 or 1 and  $R^{32}$  represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom,  $C_{1-4}$  alkyl, or  $C_{1-4}$  alkoxy.

19. The compound according to claim 5, wherein X represents CH or N;

any one of  $R^{21}$  and  $R^{22}$  represents unsubstituted  $C_{1-4}$  alkoxy and the other represents group  $R^{31}$ -( $CH_2$ )p-O-;

 $R^{23}$ ,  $R^{25}$ , and  $R^{26}$  represent a hydrogen atom;

 $R^{24}$  represents a halogen atom,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, or nitro;

 $R^{27}$  and  $R^{28}$  represent a hydrogen atom; and

 $R^{29}$  represents  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or  $C_{2-6}$  alkynyl (which  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, and  $C_{2-6}$  alkynyl each are optionally substituted by a halogen atom or  $C_{1-4}$  alkoxy), or  $-(CH_2)q-R^{32}$  wherein q is an integer of 0 or 1 and  $R^{32}$  represents phenyl, pyridyl, or naphthyl which

phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom,  $C_{1-4}$  alkyl, or  $C_{1-4}$  alkoxy.

- 20. The compound according to claim 19, wherein  $R^{21}$  represents unsubstituted  $C_{1-4}$  alkoxy and  $R^{22}$  represents group  $R^{31}$ -(CH<sub>2</sub>)p-O-.
- 21. The compound according to claim 19 or 20, wherein  $R^{31}$  represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by  $C_{1-4}$  alkyl optionally substituted by hydroxyl, or group  $R^{14}$ -(S)m- wherein  $R^{14}$  represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by  $C_{1-4}$  alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by  $C_{1-4}$  alkyl and m is 0 (zero); and p is an integer of 1 to 4.
- 22. The compound according to any one of claims 19 to 21, wherein p is 1.
- 23. The compound according to any one of claims 19 to 21, wherein  $R^{31}$  represents group  $R^{14}-(S)m-$  wherein  $R^{14}$  represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by  $C_{1-4}$  alkyl and m is 0 (zero).
- 24. The compound according to any one of claims 19 to 21, wherein  $R^{31}$  represents  $group R^{14}-(S)m-$  wherein  $R^{14}$ unsaturated six-membered heterocyclic represents an containing two nitrogen atoms group one or optionally substituted by C1-4 alkyl and m is 0 (zero) and p is 1.
  - 25. The compound according to claim 23 or 24,

wherein R14 represents optionally substituted pyridyl.

26. The compound according to claim 5, wherein X represents CH or N;

any one of  $R^{21}$  and  $R^{22}$  represents unsubstituted  $C_{1-4}$  alkoxy and the other represents group  $R^{31}$ -( $CH_2$ )p-O-;

 $R^{23}$ ,  $R^{25}$ , and  $R^{26}$  represent a hydrogen atom;

 $R^{24}$  represents a halogen atom,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, or nitro;

any one of or both  $R^{27}$  and  $R^{28}$  represent a group other than a hydrogen atom; and

 $R^{29}$  represents  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or  $C_{2-6}$  alkynyl (which  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, and  $C_{2-6}$  alkynyl each are optionally substituted by a halogen atom or  $C_{1-4}$  alkoxy), or  $-(CH_2)q-R^{32}$  wherein q is an integer of 0 or 1 and  $R^{32}$  represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom,  $C_{1-4}$  alkyl, or  $C_{1-4}$  alkoxy.

- 27. The compound according to claim 26, wherein  $R^{21}$  represents unsubstituted  $C_{1-4}$  alkoxy and  $R^{22}$  represents group  $R^{31}$ -(CH<sub>2</sub>)p-O-.
- 28. The compound according to claim 26 or 27, wherein  $R^{31}$  represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by  $C_{1-4}$  alkyl optionally substituted by hydroxyl, or group  $R^{14}$ —(S)m— wherein  $R^{14}$  represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by  $C_{1-4}$  alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by  $C_{1-4}$  alkyl and m is 0 (zero); and p is an integer of 1 to 4.
  - 29. The compound according to any one of claims 26

50b 47 to 28, wherein p is 1.

- 30. The compound according to any one of claims 26 to 28, wherein  $R^{31}$  represents group  $R^{14}$ -(S)m- wherein  $R^{14}$  represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by  $C_{1-4}$  alkyl and m is 0 (zero).
- 31. The compound according to any one of claims 26 to 28, wherein  $R^{31}$  represents group  $R^{14}-(S)m-$  wherein  $R^{14}$  represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by  $C_{1-4}$  alkyl and m is 0 (zero) and p is 1.
- 32. The compound according to claim 30 or 31, wherein R<sup>14</sup> represents optionally substituted pyridyl.
  - 33. The compound according to claim 5, wherein X represents CH or N;

any one of  $R^{21}$  and  $R^{22}$  represents unsubstituted  $C_{1-4}$  alkoxy and the other represents group  $R^{31}-(CH_2)p-O-$ ;

R<sup>23</sup>, R<sup>25</sup>, and R<sup>26</sup> represent a hydrogen atom;

 $R^{24}$  represents a halogen atom,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, or nitro;

R<sup>27</sup> represents a hydrogen atom;

 $R^{28}$  represents a group other than a hydrogen atom; and

 $R^{29}$  represents  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or  $C_{2-6}$  alkynyl (which  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, and  $C_{2-6}$  alkynyl each are optionally substituted by a halogen atom or  $C_{1-4}$  alkoxy), or  $-(CH_2)q-R^{32}$  wherein q is an integer of 0 or 1 and  $R^{32}$  represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom,  $C_{1-4}$  alkyl, or  $C_{1-4}$  alkoxy.

34. The compound according to claim 33, wherein R21

represents unsubstituted  $C_{1-4}$  alkoxy and  $R^{22}$  represents group  $R^{31}$ -(CH<sub>2</sub>)p-O-.

SUD A8

- wherein  $R^{31}$  represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by  $C_{1-4}$  alkyl optionally substituted by hydroxyl, or group  $R^{14}$ —(S)m— wherein  $R^{14}$  represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by  $C_{1-4}$  alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by  $C_{1-4}$  alkyl and m is 0 (zero); and p is an integer of 1 to 4.
- 36. The compound according to any one of claims 33 to 35, wherein p is 1.
- 37. The compound according to any one of claims 33 to 35, wherein  $R^{31}$  represents group  $R^{14}-(S)m-$  wherein  $R^{14}$  represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by  $C_{1-4}$  alkyl and m is 0 (zero).
- 38. The compound according to any one of claims 33 to 35, wherein  $R^{31}$  represents group  $R^{14}$ -(S)m- wherein  $R^{14}$ unsaturated six-membered heterocyclic represents an two nitrogen atoms and containing one o/r group optionally substituted by  $C_{1-4}$  alkyl and m is 0 (zero) and p is 1.
- 39. The compound according to claim 37 or 38, wherein  $R^{14}$  represents optionally substituted pyridyl.
  - 40. The compound according to claim 5, wherein X represents CH or N;

any one of  $R^{21}$  and  $R^{22}$  represents unsubstituted  $C_{1-4}$  always and the other represents group  $R^{31}$ -( $CH_2$ )p-0-;

R<sup>23</sup> and R<sup>26</sup> represent a hydrogen atom;

 $R^{24}$  and  $R^{25}$  represent a halogen atom,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, or nitro;

R<sup>27</sup> and R<sup>28</sup> represent a hydrogen atom;

 $R^{29}$  represents  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or  $C_{2-6}$  alkynyl (which  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, and  $C_{2-6}$  alkynyl each are optionally substituted by a halogen atom or  $C_{1-4}$  alkoxy), or  $-(CH_2)q-R^{30}$  wherein q is an integer of 0 or 1 and  $R^{32}$  represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom,  $C_{1-4}$  alkyl, or  $C_{1-4}$  alkoxy.

- 41. The compound according to claim 40, wherein  $R^{21}$  represents unsubstituted  $C_{1-4}$  alkoxy and  $R^{22}$  represents group  $R^{31}-(CH_2)p-0-$ .
- wherein  $R^{31}$  represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by  $C_{1-4}$  alkyl optionally substituted by hydroxyl, or group  $R^{14}$ —(S)m— wherein  $R^{14}$  represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by  $C_{1-4}$  alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by  $C_{1-4}$  alkyl and m is 0 (zero); and p is an integer of 1 to 4.
- 43. The compound according to any one of claims 40 to 42, wherein p is 1.
- 44. The compound according to any one of claims 40 to 42, wherein  $R^{31}$  represents group  $R^{14}$ -(S)m- wherein  $R^{14}$  represents an unsaturated six-membered heterocyclic

3 SUK

group containing one or two nitrogen atoms and optionally substituted by  $C_{1-4}$  alkyl and m is 0 (zero).

- 45. The compound according to any one of claims 40 to 42, wherein  $R^{31}$  represents group  $R^{14}-(S)m-$  wherein  $R^{14}$  represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by  $C_{1-4}$  alkyl and m is 0 (zero) and p is 1.
- 46. The compound according to claim 44 or 45, wherein R14 represents optionally substituted pyridyl.
- 47. The compound according to claim 1, which is a compound selected from the group consisting of the following compounds or a pharmaceutically acceptable salt or solvate thereof:
- (13) N-{2-chlord-4-[(6,7-dimethoxy-4-quinolyl)oxy]-phenyl}-N'-propylurea;
- (51) N-(2-chloro-4-{[6-methoxy-7-(2-morpholino-ethoxy)-4-quinolyl]oxy}phenyl)-N'-(2,4-difluorophenyl) urea;
- (62) N-{2-chloro-4-(6,7-dimethoxy-4-quinazolinyl)-oxy]phenyl}-N'-propylurea;
- (76) N-{2-chloro-4-[\(\delta\),7-dimethoxy-4-quinazolinyl)-oxy]phenyl}-N'-ethylurea;
- (117) N-{2-chloro-4-[(6,7-dimethoxy-4-quinazo-linyl)oxy]phenyl}-N'-methyluxea;
- (119) N-(2-chloro-4-{[6-methoxy-7-(3-morpholino-propoxy)-4-quinazolinyl]oxy}phenyl)-N'-propylurea;
- (135) N-(2-chloro-4-{[6-methoxy-7-(3-piperidino-propoxy)-4-quinazolinyl]oxy}phenyl)-N'-propylurea;
- (142) N-(2-chloro-4-{[6-methoxy-7-(3-pyridyl-methoxy)-4-quinolyl]oxy}phenyl)-N'-propylurea;
- (143) N-(2-chloro-4-{[6-methoxy-7-(4-pyridyl-methoxy)-4-quinolyl]oxy}phenyl)-N'\propylurea;
  - (144)  $N-(2-\text{chloro}-4-\{[6-\text{metho}xy-7-(2-\text{morpholino-})]\}$

```
ethoxy)-4-quinolyl]oxy}phenyl)-N'-propylurea;
                       (145) N-[2-chloro-4-{(6-methoxy-7-[2-(1H-1,2,3-
 triazol-1-x1)ethoxy]-4-quinolyl}oxy)phenyl]-N'-
 propylurea;
                       (146) N-[2-chloro-4-(7-\{[2-(1H-1-imidazolyl)-
 ethoxy]-6-methoxy-4-quinolyl}oxy)phenyl]-N'-propylurea;
                       (148) N-12-chloro-4-(6-methoxy-7-{[2-(4-methyl-
 piperazino)ethoxy]-4-quinolyl}oxy)phenyl]-N'-propylurea;
                       (149) N-(2\chloro-4-{[7-(2-hydroxyethoxy)-6-
 methoxy-4-quinolyl]oxy}phenyl)-N'-propylurea;
                       (151) N-(2-dhloro-4-\{[6-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-methoxy-7-(3-morpholino-meth
 propoxy)-4-quinolylloxylphenyl)-N'-propylurea;
                       (152) N-[2-ch] or 0-4-(6-methoxy-7-\{[3-(4-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methy
 piperazino)propoxy] \dagged4-quinolyl\oxy)phenyl]-N'-
 propylurea;
                       (153) N-[2-chloro-4-(6-methoxy-7-{[3-(1H-1,2,3-
 triazol-1-yl)propoxy]-4-quinolyl}oxy)phenyl]-N'-
propylurea;
                       (157) N-\{2-\text{chloro}\ 4-[(7-\{3-[(2-\text{hydroxyethyl})-
 (methyl)amino]propoxy}-6/-methoxy-4-quinolyl)oxy]-
phenyl}-N'-propylurea;
                      (159) N-\{2-\text{chloro}-4\} [(6-methoxy-7-\{[5-(1H-1,2,3-
triazol-1-yl)pentyl]oxy}-4-quinolyl)oxy]phenyl}-N'-
propylurea;
                      (160) N-[2-chloro-4-(\forall -\{[4-(1H-1-imidazoly1)-imidazoly1)-imidazoly1)
butoxy]-6-methoxy-4-quinoly1\soxy)phenyl]-N'-propylurea;
                      (162) N-(2-chloro-4-\{[6]-methoxy-7-(2-morpholino-
ethoxy)-4-quinazolinyl]oxy}phenyl)-N'-(2,4-difluoro-
phenyl)urea;
                      (163) N-(2-\text{chloro}-4-\{[6-\text{methoxy}-7-(3-\text{morpholino}-4-(3-\text{morpholino}-4)\})\}
propoxy)-4-quinazolinyl]oxy}phenyl)-N'-(2,4-difluoro-
phenyl)urea;
                      (164) N-[2-chloro-4-(6-meth)]xy-7-{[3-(4-methyl-
piperazino)propoxy]-4-quinazolinyl\oxy)phenyl]-N'-(2,4-
difluorophenyl)urea;
                      (165) N-\{2-chloro-4-[(7-\{3-[(2+hydroxyethyl)-
(methyl)amino]propoxy}-6-methoxy-4-qu\u00e4inazolinyl)oxy]-
```

phenyl-N'-(2,4-difluorophenyl)urea;

- $(168)\ N-(2-chloro-4-\{[6-methoxy-7-(3-morpholino$ propoxy)-4-quinolyl]oxy}phenyl)-N'-(2,4-difluorophenyl)-
- (169)  $N \rightarrow (2-\text{chloro}-4-\{[6-\text{methoxy}-7-(3-\text{pyridy}]$ methoxy)-4-quinolyl]oxy}phenyl)-N'-(2,4-difluorophenyl)urea;
- (170)  $N-[2-chloro-4-(6-methoxy-7-\{[2-(1H-1,2,3-methoxy-7-(2-(1H-1,2,3-methoxy-7-(2-(1H-1,2,3-methoxy-7-(2-(1H-1,2,3-methoxy-7-(2-(1H-1,2,3-methoxy-7-(2-(1H-1,2,3-methoxy-7-(1H-1,2,3-me$  $triazol-1-yl)ethoxy]-4-quinolyl}oxy)phenyl]-N'-(2,4$ difluorophenyl)urea;
- (184)  $N-(2-chl)pro-4-\{[6-methoxy-7-(3-piperidino$ propoxy)-4-quinazolinyl]oxy}phenyl)-N'-methylurea;
- (185)  $N-(2-\text{chlo}_{0}-4-\{[6-\text{methoxy}-7-(3-\text{piperidino-})]\}$ propoxy)-4-quinazoliny[]oxy]phenyl)-N'-ethylurea; and
- (186)  $N-(2-\text{chloro}+4-\{[6-\text{methoxy}-7-(4-\text{pyridy})$  $methoxy)-4-quinolyl]oxy\phenyl)-N'-(2,4-difluorophenyl)$ urea.
- 48. A pharmaceutical composition comprising active ingredient the compound according to any one of claims 1 to 47 or a pharmaceutically acceptable salt or solvate thereof.
- The pharmaceutical composition according to claim 48, for use in the treatment of a disease selected from the group consisting of stumor, diabetic retinopathy, psoriasis, atherosclerosis, chronic rheumatism, Kaposi's sarcoma.

50. Use of the compound according to any one of claims 1 to 47 or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a therapeutic agent for use in the treatment  $\phi f$  a disease selected from the group consisting of tumor, \diabetic retinopathy, atherosclerosis, chronic rheumatism, psoriasis, and Kaposi's sarcoma.

- 51. A method for treating a disease selected from the group consisting of tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, and Kaposi's sarcoma, comprising the step of administering an effective amount of the compound according to any one of claims 1 to 47 or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier, to mammals.
- 52. A method for inhibiting the angiogenesis of target blood vessels, comprising the step of making the compound according to any one of claims 1 to 47 or a pharmaceutically acceptable salt or solvate thereof in contact with vascular endothelial cells of the target blood vessels.